- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
- Interventions
- Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA), Intensive chemotherapy with 7 + 3
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 33
- States / cities
- Newport Beach, California • Palo Alto, California • Denver, Colorado + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Interventions
- Cytarabine, Decitabine, Idarubicin, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment, Questionnaire Administration, Azacitidine, Venetoclax, glasdegib
- Drug · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Alvocidib, Cytarabine, Daunorubicin
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Pevonedistat, Venetoclax, Azacitidine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 23
- States / cities
- Gilbert, Arizona • La Jolla, California • Orange, California + 20 more
- Conditions
- Adult, Myelodysplastic Syndromes
- Interventions
- questionnaire administration, fatigue assessment and management, observation, quality-of-life assessment
- Other
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 927 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia
- Interventions
- amifostine trihydrate, cytarabine, idarubicin
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Milademetan, AZA
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 5
- States / cities
- Duarte, California • San Francisco, California • Fairway, Kansas + 2 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- combination therapy using decitabine and midostaurin
- Drug
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Acute Myeloid Leukemia, Leukemia, Myeloid
- Interventions
- Bioelectrical Impedence Analysis Device, 6 Minute Walk Test, Computed Tomography Scans to Measure Skeletal Muscular Index, Blood Test/Blood Draw, Hand Grip Strength Test
- Device · Other · Diagnostic Test
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 239 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ropeginterferon, Alfa-2b, Azacitidine, MDS/AML
- Interventions
- ropeginterferon alfa- 2b, Azacitidine (AZA)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Vyxeos, Gemtuzumab Ozogamicin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Panobinostat
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 5
- States / cities
- Stanford, California • Boston, Massachusetts • Columbus, Ohio + 2 more
- Conditions
- Leukemia
- Interventions
- choline magnesium trisalicylate, Dexamethasone
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- AML - Acute Myeloid Leukemia
- Interventions
- Dexamethasone plus Venetoclax-based Low-Intensity Therapy
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Combination Product
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more
- Conditions
- Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Interventions
- gilteritinib, azacitidine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Chicago, Illinois + 7 more
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Untreated Adult Acute Myeloid Leukemia, Myeloproliferative Neoplasm With 10% Blasts or Higher
- Interventions
- filgrastim, clofarabine, cytarabine
- Biological · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 3
- States / cities
- Duarte, California • Stanford, California • Seattle, Washington
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Velcade, Idarubicin
- Drug
- Lead sponsor
- University of Kentucky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Rochester, New York
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Core Binding Factor Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Interventions
- Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 65
- States / cities
- Lewes, Delaware • Newark, Delaware • Orlando, Florida + 44 more
- Conditions
- Leukemia
- Interventions
- cytarabine, idarubicin, pravastatin sodium
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 185
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 123 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, ITMHA, Idarubicin, Fludarabine, Mitoxantrone, Erwinia asparaginase, Sorafenib, G-CSF, Dexrazoxane, Stem Cell Transplant, Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
- Drug · Combination Product · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 29 Days to 21 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 10
- States / cities
- Madera, California • Orange, California • Palo Alto, California + 7 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- A arm (DA-90), B arm (DAC), A arm (CLAG-M), B arm (FLAG-IDA)
- Drug
- Lead sponsor
- Polish Adult Leukemia Group
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
- Interventions
- DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF
- Biological · Drug
- Lead sponsor
- David Avigan
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts